Mast Therapeutics touts interim data from pulmonary hypertension study

Mast Therapeutics (NYSE:MSTX) touted interim data from a Phase II study of its AIR001 candidate in patients with pulmonary hypertension (PH) and PH associated with heart failure with preserved ejection fraction. Positive interim results from the ongoing trial were published in the Journal of Clinical Investigation. The San Diego-based company enrolled 50 patients to study its nebulized inhaled nitrite and interim results showed that AIR001 significantly decreased pulmonary, right atrial and pulmonary capillary wedge pressures. The change was most prominent in patients with PH associated with heart failure with preserved ejection fraction. Get the full story at our sister site, Drug Delivery Business News. The post Mast Therapeutics touts interim data from pulmonary hypertension study appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiovascular Clinical Trials Drug-Device Combinations Mast Therapeutics Source Type: news